MD Anderson Cancer Center
The University of Texas
Houston, TX
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Accepting patients
SUCCESSOR-1
Phase 3 Clinical Trial Evaluating the Safety and Effectiveness of Investigational Drug Mezigdomide in Combination with Bortezomib and Dexamethasone Compared to Pomalidomide, Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Learn more- CELMoD
- Randomization
- Phase 3
Accepting patients
MonumenTAL-3
Phase 3 Clinical Trial Comparing the Efficacy of an Investigational Medication Combined with Daratumumab or Daratumumab and Pomalidomide Versus Daratumumab, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.
Learn more- Bispecific Antibody
- GPRC5D
- Randomization
- Phase 3
Accepting patients
Personalized Natural Killer Cell Therapy
Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma
Learn more- Natural Killer Cells (Allogeneic)
- Phase 2
Accepting patients
QUINTESSENTIAL
A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
Learn more- CAR T Cell
- GPRC5D
- Phase 2
Accepting patients
KarMMa-9
Phase 3 Clinical Trial Comparing the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance to Approved Lenalidomide Maintenance Alone in Patients with Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Stem Cell Transplant
Learn more- CAR T Cell
- Immunomodulatory Drug
- BCMA
- Randomization
- Phase 3
Accepting patients
CA088-1005
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Learn more- CAR T Cell
- CELMoD
- GPRC5D
- Phase 1
Not yet accepting
LINKER-MM3
A Trial to Learn How Well Linvoseltamab works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants with Relapsed/Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
Not yet accepting
DREAMM5
Platform Study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
Learn more- Antibody Drug Conjugate (ADC)
- Gamma-Secretase Inhibitor
- BCMA
- Phase 2
- Has results
Accepting patients
ADVANCE
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (ADVANCE)
Learn more- Monoclonal Antibody
- CD38
- Phase 2
Accepting patients
MagnetisMM-4
Phase 1/2 Clinical Trial Evaluating the Safety, Effectiveness and Best Dose of Elranatamab Combined with Different Anti-Cancer Therapies in Participants with Multiple Myeloma
Learn more- Bispecific Antibody
- Gamma-Secretase Inhibitor
- BCMA
- Phase 1/2
8 hidden based on your filters. Show All